These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 1465648

  • 1. Case report 744. Deferoxamine-induced skeletal dysplasia.
    Borenstein ZC, Hyman CB, Rimoin DL, Chapman CL, Lachman R.
    Skeletal Radiol; 1992; 21(8):534-7. PubMed ID: 1465648
    [No Abstract] [Full Text] [Related]

  • 2. MR imaging of deferoxamine-induced bone dysplasia in an 8-year-old female with thalassemia major.
    Miller TT, Caldwell G, Kaye JJ, Arkin S, Burke S, Brill PW.
    Pediatr Radiol; 1993; 23(7):523-4. PubMed ID: 8309753
    [Abstract] [Full Text] [Related]

  • 3. Deferoxamine-induced dysplasia-like skeletal abnormalities at radiography and MRI.
    Seif El Dien HM, Esmail RI, Magdy RE, Lotfy HM.
    Pediatr Radiol; 2013 Sep; 43(9):1159-65. PubMed ID: 23563594
    [Abstract] [Full Text] [Related]

  • 4. Deferoxamine-induced dysplasia of the knee: sonographic features and diagnostic performance compared with magnetic resonance imaging.
    Chan YL, Chu CW, Chik KW, Pang LM, Shing MK, Li CK.
    J Ultrasound Med; 2001 Jul; 20(7):723-8. PubMed ID: 11444730
    [Abstract] [Full Text] [Related]

  • 5. Deferoxamine-induced bone dysplasia in patients with thalassemia major.
    Brill PW, Winchester P, Giardina PJ, Cunningham-Rundles S.
    AJR Am J Roentgenol; 1991 Mar; 156(3):561-5. PubMed ID: 1899759
    [Abstract] [Full Text] [Related]

  • 6. Patterns of bone diseases in transfusion-dependent homozygous thalassaemia major: predominance of osteoporosis and desferrioxamine-induced bone dysplasia.
    Chan YL, Pang LM, Chik KW, Cheng JC, Li CK.
    Pediatr Radiol; 2002 Jul; 32(7):492-7. PubMed ID: 12107582
    [Abstract] [Full Text] [Related]

  • 7. Desferrioxamine-induced long bone changes in thalassaemic patients - radiographic features, prevalence and relations with growth.
    Chan YL, Li CK, Pang LM, Chik KW.
    Clin Radiol; 2000 Aug; 55(8):610-4. PubMed ID: 10964732
    [Abstract] [Full Text] [Related]

  • 8. Deferoxamine-induced bone dysplasia in the distal femur and patella of pediatric patients and young adults: MR imaging appearance.
    Chan Y, Li C, Chu WC, Pang L, Cheng JC, Chik KW.
    AJR Am J Roentgenol; 2000 Dec; 175(6):1561-6. PubMed ID: 11090375
    [Abstract] [Full Text] [Related]

  • 9. Growth hormone secretion and bone histomorphometric study in thalassaemic patients with acquired skeletal dysplasia secondary to desferrioxamine.
    De Sanctis V, Stea S, Savarino L, Scialpi V, Traina GC, Chiarelli GM, Sprocati M, Govoni R, Pezzoli D, Gamberini R, Rigolin F.
    J Pediatr Endocrinol Metab; 1998 Dec; 11 Suppl 3():827-33. PubMed ID: 10091153
    [Abstract] [Full Text] [Related]

  • 10. Long-term follow-up of skeletal dysplasia in thalassaemia major.
    Naselli A, Vignolo M, Di Battista E, Garzia P, Forni GL, Traverso T, Aicardi G.
    J Pediatr Endocrinol Metab; 1998 Dec; 11 Suppl 3():817-25. PubMed ID: 10091152
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Growth failure and bone lesions due to desferrioxamine in thalassaemic patients.
    Caruso-Nicoletti M, Di Bella D, Pizzarelli G, Leonardi C, Sciuto C, Coco M, Di Gregorio F.
    J Pediatr Endocrinol Metab; 1998 Dec; 11 Suppl 3():957-60. PubMed ID: 10091171
    [No Abstract] [Full Text] [Related]

  • 13. Deferoxamine in thalassemia major.
    Cazzola M, Locatelli F, De Stefano P.
    N Engl J Med; 1995 Jan 26; 332(4):271-2; author reply 272-3. PubMed ID: 7808503
    [No Abstract] [Full Text] [Related]

  • 14. Compliance and satisfaction with deferasirox (Exjade®) compared with deferoxamine in patients with transfusion-dependent beta-thalassemia.
    Haghpanah S, Zarei T, Zahedi Z, Karimi M.
    Hematology; 2014 Jun 26; 19(4):187-91. PubMed ID: 24074344
    [Abstract] [Full Text] [Related]

  • 15. Deferoxamine-induced platyspondyly in hypertransfused thalassemic patients.
    Levin TL, Sheth S, Berdon WE, Ruzal-Shapiro C, Piomelli S.
    Pediatr Radiol; 1995 Nov 26; 25 Suppl 1():S122-4. PubMed ID: 8577502
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major.
    Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, Allen CJ, Farrell DE, Harris JW.
    N Engl J Med; 1994 Sep 01; 331(9):567-73. PubMed ID: 8047080
    [Abstract] [Full Text] [Related]

  • 17. Desferrioxamine therapy induces clearance of iron deposits after bone marrow transplantation for thalassemia: case report.
    Giardini C, La Nasa G, Contu L, Galimberti M, Polchi P, Angelucci E, Baronciani D, Barbanti I, Muretto P, Lucarelli G.
    Bone Marrow Transplant; 1993 Sep 01; 12 Suppl 1():108-10. PubMed ID: 8374548
    [No Abstract] [Full Text] [Related]

  • 18. Dose-dependent pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine.
    Rego EM, Neto EB, Simões BP, Zago MA.
    Am J Hematol; 1998 Aug 01; 58(4):340-1. PubMed ID: 9692403
    [No Abstract] [Full Text] [Related]

  • 19. Rachitic rosary in a well chelated thalassaemic patient with primary amenorrhea (patient report).
    Lauriola AL, Tangerini A, Lodi A, Gamberini MR, Testa MR, Orzincolo C, De Sanctis V, Vullo C.
    J Pediatr Endocrinol Metab; 1998 Aug 01; 11 Suppl 3():979-80. PubMed ID: 10091177
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.